A Phase 1b Study of the Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Citarinostat (Primary) ; Ipilimumab; Nivolumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Acetylon Pharmaceuticals; Celgene Corporation
- 12 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Dec 2017.
- 05 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.
- 05 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.